HDAC6 and B-cell chronic lymphocytic leukemia: After CLL engraftment was established, mice were randomized, and Eμ-TCL1 recipients were treated orally with a selective HDAC6 inhibitor, ACY738 (20), or vehicle (Figure 1A).